Market Place
Sourcing Support
Revive Focuses On Bucillamine For Infectious Diseases
18 Sep 2024 //
GLOBENEWSWIRE
Revive Therapeutics Updates On Bucillamine Research For Nerve Agents
28 Aug 2024 //
GLOBENEWSWIRE
Revive Therapeutics Updates On Bucillamine For Nerve Agent Exposure Study
02 Jul 2024 //
GLOBENEWSWIRE
Revive Therapeutics Updates On FDA Meeting For Long COVID Study
12 Jun 2024 //
GLOBENEWSWIRE
Revive Requests FDA Meeting for Bucillamine Long COVID Study
23 Apr 2024 //
GLOBENEWSWIRE
Revive Submits Type C Meeting Request Package to FDA for trial of Bucillamine
27 Mar 2024 //
GLOBENEWSWIRE
Revive To Submit Type C Meeting Request with FDA for Bucillamine to Treat COVID
19 Mar 2024 //
GLOBENEWSWIRE
Revive Provides Update Evaluating Bucillamine for Nerve Agent Exposure
16 Jan 2024 //
GLOBENEWSWIRE
Revive Completes Development of Lyophilized Formulation of Bucillamine
10 Jan 2024 //
GLOBENEWSWIRE
Revive Therapeutics Collaborates with Attwill Medical Solutions
18 Dec 2023 //
GLOBENEWSWIRE
Revive Enters into Agreement with Defence R&D for Evaluating Bucillamine
17 Oct 2023 //
GLOBENEWSWIRE
Revive Therapeutics Announces Filing of Patent for Bucillamine
28 Jul 2023 //
GLOBENEWSWIRE
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine
30 May 2023 //
GLOBENEWSWIRE
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine
12 May 2023 //
GLOBENEWSWIRE
Revive Announces Data Safety Monitoring Board Meeting Pha3 Study of Bucillamine
02 May 2023 //
GLOBENEWSWIRE
Revive Provides Phase 3 Study for Bucillamine in the Treatment of COVID-19
20 Mar 2023 //
GLOBENEWSWIRE
Revive Provides Update From Type C Meeting with FDA forfor Bucillamine
08 Mar 2023 //
GLOBENEWSWIRE
Revive Therapeutics Announces Submission of Type C Meeting Request
22 Dec 2022 //
GLOBENEWSWIRE
Revive Therapeutics Provides Update on Pha3 Clinical Trial for Bucillamine
06 Oct 2022 //
GLOBENEWSWIRE
Revive Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
16 Aug 2022 //
GLOBENEWSWIRE
Revive Therapeutics Provides Update on PIII Trial for Bucillamine in COVID-19
25 Jul 2022 //
GLOBENEWSWIRE
Revive Therapeutics Provides Update on PIII Trial for Bucillamine in COVID-19
06 Jun 2022 //
GLOBENEWSWIRE
Revive Therapeutics Provides Update on PIII Trial for Bucillamine in COVID-19
16 May 2022 //
GLOBENEWSWIRE
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine
25 Apr 2022 //
GLOBENEWSWIRE
Revive Therapeutics Receives FDA ODD for Bucillamine
15 Feb 2022 //
GLOBENEWSWIRE
Revive Tx Provides Update on Phase 3 Trial for Bucillamine in COVID-19
19 Jan 2022 //
GLOBENEWSWIRE
Revive Clarifies Status of Phase 3 Clinical Trial for Bucillamine in COVID-19
06 Jan 2022 //
GLOBENEWSWIRE
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine
29 Dec 2021 //
GLOBENEWSWIRE
Revive Files for FDA Orphan Drug Designation for Bucillamine
23 Nov 2021 //
GLOBENEWSWIRE
Revive Provides Update on FDA Phase 3Trial for Bucillamine in COVID-19
26 Oct 2021 //
GLOBENEWSWIRE
Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine
08 Jun 2021 //
GLOBENEWSWIRE
Revive Provides Update on FDA Phase 3 Clinical Trial for Bucillamine
23 Dec 2020 //
GLOBENEWSWIRE
Revive Provides Update on FDA Phase 3 Clinical Trial for Bucillamine
23 Dec 2020 //
GLOBENEWSWIRE
Revive Therapeutics Announces IRB Approval of US Expanded Access for Bucillamine
16 Sep 2020 //
GLOBENEWSWIRE
Revive Therapeutics Announces IRB Approval for Bucillamine in COVID-19
31 Aug 2020 //
GLOBENEWS WIRE
Revive Announces Submission of IRB Approval for Ph3 Trial Protocol Bucillamine
26 Aug 2020 //
GLOBENEWSWIRE
Revive Therapeutics receives US FDA nod to begin phase 3 trial of Bucillamine
21 Aug 2020 //
PHARMABIZZ
Revive Update Following U.S. FDA Approval of Ph3 Trial for Bucillamine
05 Aug 2020 //
GLOBENEWSWIRE
Revive Announces U.S. FDA Approval of Confirmatory PH3 Trial for Bucillamine
31 Jul 2020 //
GLOBENEWSWIRE
Revive Therapeutics Announces Filing of a Pre-CTA Meeting Request Health Canada
03 Jun 2020 //
GLOBENEWSWIRE
